Novel Neonatal/Pediatric Endotracheal Tube Technology ID: 2015-061

A groundbreaking endotracheal tube designed to significantly reduce intubation-related complications in neonates and newborns.

Technology Overview

This technology focuses on a novel endotracheal tube (ETT) for neonatal and pediatric care, featuring a lubricious hydrogel coating to minimize mucosal friction and prevent bacterial biofilm formation. Developed by Carl Genberg, Ronald Bracken, and Paul Savage and assigned to Brigham Young University, this innovation aims to mitigate common complications associated with mechanical ventilation, such as bronchopulmonary dysplasia (BPD) and subglottic stenosis. Preliminary tests have shown promising results in maintaining tracheal integrity, with the hydrogel technology being exclusively licensed by N8 Medical from Hydromer Inc.

Key Advantages

• Reduces mucosal friction, lowering the risk of intubation-related injuries
• Prevents bacterial biofilm formation, reducing the incidence of ventilation-associated infections
• Proven effectiveness in preliminary animal studies, demonstrating improved tracheal integrity
• Addresses a significant unmet need in neonatal care, particularly in regions with high incidences of neonatal respiratory issues

Problems Addressed

• Reduction in bronchopulmonary dysplasia (BPD) and subglottic stenosis associated with mechanical ventilation
• Decrease in the risk of ventilation-associated infections
• Addresses the lack of specialized ETTs for neonates and newborns in high-need regions

Additional Information

Technology ID: 2015-061
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025